Systematic review / meta-analysisHuman
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Endocrinology, diabetes & metabolism, 2026 Mar. Abulehia A, Ayesh H, Ayesh O and 7 others.
Study type
Systematic review / meta-analysis
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Endocrinology, diabetes & metabolism
Published
2026 Mar
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansDiabetes Mellitus, Type 2Randomized Controlled Trials as TopicObesityHypoglycemic AgentsWeight LossReceptors, GlucagonTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobin
Other papers on Mazdutide
Randomized controlled trial · 2026
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial
Randomized controlled trial · 2025Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Randomized controlled trial · 2023A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page